Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow‐up of the Eastern Cooperative Oncology Group E3A98 trial
暂无分享,去创建一个
H. Uno | S. Rajkumar | M. Gertz | P. Greipp | R. Abonour | L. Heffner | Philip R. Greipp
[1] B. Barlogie,et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. , 2009, Blood.
[2] E. Kimby,et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Ho,et al. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial , 2008, Annals of Hematology.
[4] R. Fonseca,et al. Waldenström macroglobulinaemia , 2007, British journal of haematology.
[5] E. Kimby,et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. , 2006, Blood.
[6] E. Kimby,et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. , 2006, Clinical lymphoma & myeloma.
[7] E. Kimby,et al. Extended rituximab therapy in Waldenström's macroglobulinemia. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] M. Dimopoulos,et al. Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression , 2004, Leukemia & lymphoma.
[9] M. Rue,et al. Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98) , 2004, Leukemia & lymphoma.
[10] J. Crowley,et al. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003). , 2003, Seminars in oncology.
[11] A. Pestronk,et al. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.
[12] J. Byrd,et al. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.
[13] J. Byrd,et al. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia , 2001, Journal of immunotherapy.